BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33002230)

  • 41. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study.
    Agresti R; Sandri M; Gennaro M; Bianchi G; Maugeri I; Rampa M; Capri G; Carcangiu ML; Trecate G; Riggio E; Lozza L; de Braud F
    Clin Breast Cancer; 2017 Jun; 17(3):219-231. PubMed ID: 28087389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
    Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
    Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE;
    Breast Cancer Res Treat; 2006 Sep; 99(2):203-8. PubMed ID: 16541308
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sentinel lymph node biopsy in patients with previous ipsilateral complete axillary lymph node dissection.
    Kaur P; Kiluk JV; Meade T; Ramos D; Koeppel W; Jara J; King J; Cox CE
    Ann Surg Oncol; 2011 Mar; 18(3):727-32. PubMed ID: 20593244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
    Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
    Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.
    Namura M; Tsunoda H; Kobayashi D; Enokido K; Yoshida A; Watanabe T; Suzuki K; Nakamura S; Yamauchi H; Hayashi N
    Clin Breast Cancer; 2019 Aug; 19(4):278-285. PubMed ID: 30975473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.
    Lin J; Lin KJ; Wang YF; Huang LH; Chen SL; Chen DR
    BMC Cancer; 2020 May; 20(1):451. PubMed ID: 32434493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Incidence of axillary recurrence after a negative sentinel lymph node result in early stages of breast cancer: a 5-year follow-up].
    Ruano Pérez R; Ramos Boyero M; García-Talavera Fernández JR; Ramos Grande T; González-Orús JM; Gómez-Caminero López F; García Macias MC; Martín de Arriba A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):173-7. PubMed ID: 23067685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Corona SP; Bortul M; Scomersi S; Bigal C; Bottin C; Zanconati F; Fox SB; Giudici F; Generali D
    Breast Cancer Res Treat; 2020 Apr; 180(3):735-745. PubMed ID: 32060782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
    Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
    Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.
    Fastner G; Reitsamer R; Ziegler I; Zehentmayr F; Fussl C; Kopp P; Peintinger F; Greil R; Fischer T; Deutschmann H; Sedlmayer F
    Int J Cancer; 2015 Mar; 136(5):1193-201. PubMed ID: 24995409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment.
    Rubio IT; Esgueva-Colmenarejo A; Espinosa-Bravo M; Salazar JP; Miranda I; Peg V
    Ann Surg Oncol; 2016 Jan; 23(1):38-43. PubMed ID: 26514120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
    Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
    J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
    van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
    Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of axillary ultrasound (AUS) on axillary dissection in breast conserving surgery (BCS).
    Reyna C; Kiluk JV; Frelick A; Khakpour N; Laronga C; Lee MC
    J Surg Oncol; 2015 Jun; 111(7):813-8. PubMed ID: 25753101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.